Suzhou Ribo Life Science Announces EMA Approval for Phase 2b Clinical Trial of Vortosiran (RBD4059) in Stroke Prevention for Atrial Fibrillation Patients
Suzhou Ribo Life Science Co., Ltd. (Stock Code: 6938) has announced a significant milestone in its research and development pipeline. The European Medicines Agency (EMA) has granted approval for the initiation of a Phase 2b multi-regional clinical trial (MRCT) of its core product, vortosiran (RBD4059), which is being developed as a first-in-class small interfering RNA (siRNA) therapy for stroke prevention in patients with atrial fibrillation (SPAF).
Key Points for Investors
- EMA Approval: The European Medicines Agency’s authorization allows the company to initiate a Phase 2b trial, named ORBIT-XI-AF, across multiple regions. This marks a critical step in the global clinical development of vortosiran.
- Innovative Therapy: Vortosiran is described as the world’s first and most advanced siRNA therapy targeting Factor XI (FXI), which plays a key role in the coagulation pathway. The drug is based on the company’s proprietary RiboGalSTAR™ liver-targeting platform.
- Differentiated Mechanism: By selectively suppressing FXI synthesis in the liver, vortosiran inhibits the intrinsic coagulation pathway, potentially offering potent antithrombotic activity while reducing the risk of spontaneous bleeding—a major concern with current anticoagulant therapies.
- Strong Genetic Rationale: Human genetic data indicate that individuals with naturally low FXI levels are protected from thrombotic diseases without increased bleeding risk, making FXI inhibition a highly attractive target for safer anticoagulation.
- Global Development Strategy: The Phase 2b trial is a multi-regional clinical trial (MRCT), underscoring the company’s ambitions to bring vortosiran to international markets.
Price Sensitive and Shareholder-Relevant Information
- Milestone Achievement: The EMA approval for this clinical trial is a material development that significantly advances the global profile of Suzhou Ribo Life Science and its pipeline. This could positively influence investor sentiment and potentially impact share price, as it de-risks the drug’s development and paves the way for further regulatory and commercial progress.
- Risks Remain: The company cautions that vortosiran may not ultimately be successfully developed or commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
- Leadership: The announcement is authorized by Chairman Dr. LIANG Zicai, with the board consisting of experienced executive, non-executive, and independent directors.
Additional Details
- Date of Announcement: July 28, 2026
- Trial Name: ORBIT-XI-AF
- Drug Platform: RiboGalSTAR™
- Therapeutic Area: Stroke prevention in atrial fibrillation patients (SPAF)
- Potential Market Impact: If successful, vortosiran could set a new standard in anticoagulation therapy, combining efficacy with improved safety over existing therapies.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. The development and commercialization of pharmaceutical products are subject to significant risks and uncertainties. Investors should conduct their own due diligence and consult professional advisors before making investment decisions.
蘇州瑞博生物科技宣布EMA批准Vortosiran（RBD4059）用於房顫預防中風的IIb期臨床試驗
蘇州瑞博生物科技股份有限公司（股份代號：6938） 公布了一項重大里程碑：歐洲藥品管理局（EMA）已批准啟動旗下核心產品 vortosiran（RBD4059） 的多區域IIb期臨床試驗（MRCT），該產品是全球首個也是最先進的針對第XI因子（FXI）的siRNA療法，針對房顫患者（SPAF）的中風預防。
投資者重點資訊
- EMA批准： EMA的授權允許公司啟動名為ORBIT-XI-AF的IIb期多區域臨床試驗，這是vortosiran全球臨床開發的重要一步。
- 創新療法： vortosiran被描述為全球首個也是最先進的針對FXI的siRNA療法，基於公司專有的 RiboGalSTAR™ 肝臟靶向平台。
- 差異化機制： vortosiran通過選擇性抑制肝臟合成FXI，阻斷內源性凝血途徑，可能在減少自發性出血風險的同時，提供強效的抗血栓活性，這是現有抗凝療法的一大難題。
- 強大遺傳學依據： 人體遺傳學數據顯示，自然低FXI水平的人群能預防血栓病變且不增加出血風險，使FXI成為開發更安全抗凝藥物的理想靶點。
- 全球開發策略： IIb期試驗屬於多區域臨床試驗，顯示公司有意將vortosiran推向國際市場。
對股東可能有價格敏感/影響股價的訊息
- 重要里程碑： EMA對臨床試驗的批准，對提升公司全球地位及產品管線有重大正面影響，有機會提振投資者信心並推動股價上升，因為進一步降低了藥物開發的不確定性。
- 風險提示： 公司提醒vortosiran最終可能無法成功開發或商業化，股東及潛在投資者在買賣公司股份時須審慎行事。
- 管理層： 公告由董事長梁子才博士授權發布，管理層由多位資深執行董事、非執行董事及獨立董事組成。
其他細節
- 公告日期： 2026年7月28日
- 試驗名稱： ORBIT-XI-AF
- 藥物平台： RiboGalSTAR™
- 適應症： 房顫患者中風預防（SPAF）
- 市場潛力： 若試驗成功，vortosiran有望成為新一代抗凝治療標準，兼具更佳安全性與療效。
免責聲明
本文僅供資訊參考，並不構成投資建議。藥物研發及商業化存在重大風險與不確定性，投資者應自行審慎評估及諮詢專業意見後再作出投資決定。
